2019
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, Botteri E, Brasky TM, Brinton LA, Chen C, Doherty JA, Lu L, McCann SE, Moysich KB, Olson S, Petruzella S, Palmer JR, Prizment AE, Schairer C, Setiawan VW, Spurdle AB, Trabert B, Wentzensen N, Wilkens L, Yang HP, Yu H, Risch HA, Jordan SJ. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals Of Oncology 2019, 30: 310-316. PMID: 30566587, PMCID: PMC6386026, DOI: 10.1093/annonc/mdy541.Peer-Reviewed Original ResearchConceptsNon-aspirin nonsteroidal anti-inflammatory drugsNonsteroidal anti-inflammatory drugsEndometrial Cancer ConsortiumEndometrial cancerAnti-inflammatory drugsObese womenOdds ratioCancer ConsortiumStudy-specific odds ratiosLogistic regressionStandard-dose aspirinUse of aspirinUse of acetaminophenConfidence intervalsTimes/weekCase-control studyRisk of cancerMixed-effects logistic regressionLow-dose formulationsLeast weekly useNormal weightPooled analysisInverse associationStratified analysisReduced risk
2017
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium
Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Ness R, Edwards R, Jensen A, Kjær S, Høgdall E, Berchuck A, Cramer D, Terry K, Poole E, Bandera E, Paddock L, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Pearce C, Wu A, Pike M, Webb P. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal Of Cancer 2017, 116: 1223-1228. PMID: 28350790, PMCID: PMC5418444, DOI: 10.1038/bjc.2017.68.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsDisease-specific survivalOvarian cancer survivalAnalgesic useCancer survivalOvarian cancerInvasive epithelial ovarian cancerCommon analgesic medicationsPost-diagnosis usePre-diagnosis useRegular analgesic useEpithelial ovarian cancerOvarian Cancer Association ConsortiumAnti-inflammatory drugsAnalgesic medicationOverall survivalImproved survivalPooled analysisCommon analgesicsSurvival advantageConsortium studyClear associationCancerSurvivalFurther investigation
2016
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study
Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes & Control 2016, 27: 1457-1464. PMID: 27817122, DOI: 10.1007/s10552-016-0824-4.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsUse of NSAIDsPopulation-based case-control studyCase-control studyAnti-inflammatory drugsPancreatic cancerProtective effectHistory of NSAIDsUnconditional multivariable logistic regressionSelective COX-2 inhibitorsMultivariable logistic regressionPancreatic cancer riskSex-matched controlsCOX-2 inhibitorsPancreatic cancer studiesStatin useMedication useSmoking statusCancer riskMedication sectionStatinsCancerLogistic regressionMore frequent usersCancer studies
2015
Age‐specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium
Drahos J, Xiao Q, Risch HA, Freedman ND, Abnet CC, Anderson LA, Bernstein L, Brown L, Chow W, Gammon MD, Kamangar F, Liao LM, Murray LJ, Ward MH, Ye W, Wu AH, Vaughan TL, Whiteman DC, Cook MB. Age‐specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium. International Journal Of Cancer 2015, 138: 55-64. PMID: 26175109, PMCID: PMC4607633, DOI: 10.1002/ijc.29688.Peer-Reviewed Original ResearchConceptsBody mass indexNonsteroidal anti-inflammatory drugsRecurrent gastroesophageal refluxGastroesophageal refluxOlder age groupsAge groupsOdds ratioInternational BEACON ConsortiumRisk factor profileMultivariable logistic regressionEsophagogastric junction adenocarcinomaConfidence intervalsCase-control studyAge-specific associationsAge-specific riskAnti-inflammatory drugsEsophageal Adenocarcinoma ConsortiumIndividual participant dataInternational Barrett'sNSAID useJunction adenocarcinomaMass indexSmoking statusCigarette smokingEA patients
2014
Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Group T, Risch H, Rossing M, Doherty J, Goodman M, Lurie G, Kjær S, Hogdall E, Jensen A, Cramer D, Terry K, Vitonis A, Bandera E, Olson S, King M, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pearce C, Pike M, Berchuck A, Schildkraut J, Wentzensen N, Consortium O. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal Of The National Cancer Institute 2014, 106: djt431. PMID: 24503200, PMCID: PMC3924755, DOI: 10.1093/jnci/djt431.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAnti-Inflammatory Agents, Non-SteroidalAnticarcinogenic AgentsAspirinAustraliaCarcinoma, Ovarian EpithelialCase-Control StudiesData CollectionDenmarkDrug Administration ScheduleFemaleHumansIncidenceLogistic ModelsNeoplasms, Glandular and EpithelialOdds RatioOvarian NeoplasmsProtective AgentsRiskUnited KingdomUnited StatesConceptsNonaspirin nonsteroidal anti-inflammatory drugsNonaspirin NSAIDsInvasive epithelial ovarian cancerNonsteroidal anti-inflammatory drugsLow-dose aspirinEpithelial ovarian cancerOvarian cancerAnti-inflammatory drugsAspirin useAcetaminophen useOdds ratioPopulation-based case-control studyDaily aspirin usersRegular aspirin useOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumHigh-dose usageDose of useAspirin regimenAnalgesic useAspirin usersCardiovascular eventsDose aspirinCase patients
2011
Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis
Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow W, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH. Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis. Gastroenterology 2011, 142: 442-452.e5. PMID: 22108196, PMCID: PMC3488768, DOI: 10.1053/j.gastro.2011.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnticarcinogenic AgentsAustraliaCanadaCase-Control StudiesCohort StudiesEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansLogistic ModelsMaleMiddle AgedOdds RatioRisk AssessmentRisk FactorsStomach NeoplasmsTime FactorsUnited StatesYoung AdultConceptsNonsteroidal anti-inflammatory drugsEsophagogastric junctional adenocarcinomaRisk of EACNSAID useEsophageal adenocarcinomaPooled analysisOdds ratioEsophagogastric junctionNonaspirin nonsteroidal anti-inflammatory drugsStudy-specific odds ratiosRandom-effects meta-analysis modelEffects meta-analysis modelPrevention of adenocarcinomaUse of aspirinSignificant reduced riskPopulation-based studyConfidence intervalsAnti-inflammatory drugsDuration of useEsophageal Adenocarcinoma ConsortiumMeta-analysis modelLogistic regression modelsJunctional adenocarcinomaMedication typeEAC risk
2009
IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas
Hoyo C, Schildkraut JM, Murphy SK, Chow W, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingeart B, Mayne S, Fraumeni J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. International Journal Of Cancer 2009, 125: 2673-2678. PMID: 19626700, PMCID: PMC3008656, DOI: 10.1002/ijc.24623.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsRisk of esophagealInsulin-like growth factor 2Gastric adenocarcinomaGastric cancerEsophageal squamous cell carcinomaNoncardia gastric adenocarcinomaNoncardia gastric cancerSquamous cell carcinomaExploratory subgroup analysisAnti-inflammatory drugsMannose-6-phosphate/insulin-like growth factor 2 receptorNoncardia adenocarcinomaGrowth factor 2Cigarette smokersCell carcinomaSubgroup analysisGrowth factor 2 receptorInsulin-like growth factor 2 receptorCardia adenocarcinomaFactor 2 receptorG alleleNonsynonymous genetic variantsAdenocarcinomaStudy participants